What was the main driver of Gilead's revenue growth in the third quarter of 2006?

The primary driver of revenue growth was the strong performance of Gilead's HIV product franchise, particularly Truvada, which saw a 90% year-over-year increase in sales. The recent launch of Atripla in the U.S. also contributed significantly to the 43% overall increase in product sales for the quarter.

What is the financial impact of the Corus Pharma acquisition?

The acquisition of Corus Pharma resulted in a significant charge of $355.6 million for purchased in-process research and development (IPR&D) in the third quarter of 2006. This charge impacted the company's net income for the period, although the acquisition is expected to expand Gilead's pipeline, particularly in respiratory and infectious diseases.

How has the adoption of SFAS 123R affected Gilead's financial reporting?

Gilead adopted SFAS 123R effective January 1, 2006, which requires the expensing of stock-based compensation. This has led to an increase in reported operating expenses, particularly in R&D and SG&A, as fair value of stock options and awards are now recognized in the income statement. This also impacts earnings per share calculations.

What is the significance of the convertible senior notes issuance?

In April 2006, Gilead issued $1.30 billion in convertible senior notes. This significantly increased the company's cash and marketable securities, providing substantial financial flexibility for corporate development initiatives, including potential acquisitions like the planned $2.5 billion acquisition of Myogen. The issuance also involved convertible note hedges and warrants to manage potential dilution.

GILD 10-Q Quarterly Report Q3 FY2006 — Revenue, Net Income, EPS

Summary

Gilead Sciences reported strong top-line growth for the nine months ended September 30, 2006, with total revenues reaching $2.13 billion, a 47% increase over the same period in 2005. This growth was primarily driven by significant increases in HIV product sales, particularly Truvada, and the recent launch of Atripla. The company also saw a substantial increase in royalty revenue, largely due to higher Tamiflu sales by Roche. Financially, Gilead significantly bolstered its cash position through the issuance of convertible senior notes and related transactions, alongside strong operating cash flows. However, this quarter also saw a notable $355.6 million charge for purchased in-process research and development related to the acquisition of Corus Pharma, which impacted net income negatively for the third quarter. The company also announced plans to acquire Myogen for approximately $2.5 billion, signaling continued aggressive growth and pipeline expansion. Investors should note the ongoing strength in the HIV franchise and the strategic acquisitions aimed at diversifying the product pipeline. The adoption of SFAS 123R, expensing stock-based compensation, is also a notable factor impacting reported expenses.

Key Highlights

1Total revenues increased by 43% to $748.7 million in Q3 2006 compared to Q3 2005, driven by a 53% surge in HIV product sales.
2Truvada sales grew by 90% year-over-year in Q3 2006, reaching $309.0 million.
3Atripla, a single tablet regimen for HIV, was launched in the U.S. in July 2006 and generated $68.4 million in sales in Q3 2006.
4Royalty and contract revenue increased significantly due to higher Tamiflu royalties from Roche, totaling $62.7 million in Q3 2006.
5The company issued $1.30 billion in convertible senior notes and repurchased $544.9 million of its common stock in April 2006.
6A significant $355.6 million charge for purchased in-process R&D was recorded due to the acquisition of Corus Pharma.
7Gilead announced plans to acquire Myogen for approximately $2.5 billion, expected to close in Q4 2006.

GILEAD SCIENCES, INC. Quarterly Report for Q3 Ended Sep 30, 2006

Summary

Key Highlights

Frequently Asked Questions